Non-surgical treatment after immunotherapy for specific gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether patients with advanced gastric cancer (a specific type called dMMR/MSI-H) can be treated without surgery after receiving immunotherapy and chemotherapy. The goal is to see if this approach can control the cancer while avoiding the risks of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with advanced gastric cancer of a specific type (dMMR/MSI-H)
- Your cancer has not spread widely to other organs or invaded surrounding tissues
- You do not have another active cancer elsewhere in your body
- Your other organs (heart, lungs, liver, kidneys) are working well enough to tolerate treatment
- You are willing to participate and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well immunotherapy (drugs that boost your immune system to fight cancer) works before surgery for stomach cancer that has a specific genetic marker (dMMR or MSI-H). It aims to find factors that predict response, which may lead to more personalized and effective treatment.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This trial tests a new immunotherapy medicine (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for people with a specific type of stomach cancer (MSI-H/dMMR) that can be removed by surgery. The goal is to see if this combination helps shrink the tumor and improve outcomes before surgery.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
Hear when a new Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.